AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
企業コードATRC
会社名AtriCure Inc
上場日Aug 05, 2005
最高経営責任者「CEO」Mr. Michael H. (Mike) Carrel, CPA
従業員数1300
証券種類Ordinary Share
決算期末Aug 05
本社所在地7555 Innovation Way
都市MASON
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号45040
電話番号15137554100
ウェブサイトhttps://www.atricure.com
企業コードATRC
上場日Aug 05, 2005
最高経営責任者「CEO」Mr. Michael H. (Mike) Carrel, CPA
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし